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Recent evidence points to a plausible role of diet and the microbiome in the 
pathogenesis of both Crohn’s disease (CD) and Ulcerative Colitis (UC). Dietary 
therapies based on exclusion of table foods and replacement with nutritional formulas 
and/or a combination of nutritional formulas and specific table foods may induce 
remission in CD. In UC, specific dietary components have also been associated with 
flare of disease. While evidence of varying quality has identified potential harmful or 
beneficial dietary components, physicians and patients at the present time do not have 
guidance as to which foods are safe, may be protective or deleterious for these 
diseases. The current document has been compiled by the nutrition cluster of the 
International Organization of IBD (IOIBD) based on the best current evidence to provide 
expert opinion regarding specific dietary components, food groups and food additives 
that may be prudent to increase or decrease in the diet of patients with IBD to control 
and prevent relapse of IBD. 
 
Keywords: Crohn's disease; ulcerative colitis; meat; fruit; vegetables; food additives 
The inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis 
(UC), have long been thought to arise from inappropriate and maladaptive stimulation of 
the immune system. Emerging evidence demonstrates that environmental factors, 
including diet, may play an important role in the pathogenesis and inflammation. This 
highlights the need to provide guidance to physicians and patients regarding which foods 
may be harmful, beneficial, or safe to consume.  
To address this gap in patient care and education, the International Organization for the 
Study of Inflammatory Bowel Disease (IOIBD) formed a working group to formulate 
recommendations for physicians, dietitians, and patients based upon best available 
evidence. These recommendations focus on dietary patterns to control and prevent 
relapse of IBD. 
Methods: 
The IOIBD Nutrition Cluster is composed of 12 members from three continents 
(https://www.ioibd.org/clusters/). Following an organizational meeting in March 2018, 7 
food groups, dietary components and 5 food additives were selected as the most 
important to address for patient dietary guidance. These included dairy, red meat, 
processed meat, poultry, eggs , fruits and vegetables, fat, refined sugar, wheat and 
gluten, alcohol, emulsifiers, maltodextrins and artificial sweeteners, gums and thickening 
agents, and nanoparticles. The group assigned members to review the published 
literature for each of the chosen foods or additives. The reviewer was to summarize the 
published data separately for studies involving humans and animal models.  Animal data 
received more attention when human data was absent or the animal models were 
considered  reproducible and of clinical importance. Given the broad scope of the topic 
and the quality of the existing data, no attempt was made to produce summary risk 
estimates. 
The members prepared a concise document that included overall recommendations and 
a narrative summary. Where there were fewer data from studies in humans, more data 
were presented from animal models. Although it would be ideal to know the exact 
amount of each food that patients with IBD should consume, this could vary by age, sex, 
weight, etc. Additionally, there generally were insufficient published data for such 
specific recommendations. Therefore, recommendations were provided separately for 
CD and UC, and were chosen from 4 categories (prudent to increase consumption, to 
decrease or avoid consumption, safe to consume or insufficient evidence to make a 
claim). During group discussion, some items were modified to state that it “may be 
prudent to increase or decrease consumption.” 
The Cluster chairs (AL and JDL), in collaboration with the workgroup co-leads (JOL and 
JR) edited the first drafts to create a common format. The IOIBD cluster members 
reviewed the data and the recommendations at a face-to-face meeting in March 2019 
and voted upon the recommendations and wording, with consensus defined as >75% 
agreement. Following the meeting, the chairs slightly revised the wording of a few of the 
recommendations during the manuscript drafting in response to comments by the 
authors. Subsequently, a final vote was taken via a REDCap survey in July 2019, using 
the same definition of consensus. The evidence level (EL) supporting the 
recommendation was categorized loosely based on the following scale: randomized 
controlled trials (RCTs) provide high level evidence, observational studies in humans 
provide low level evidence and everything else is very low level evidence. Level of 
evidence could be increased or decreased based on the strength of association and 
reproducibility of findings, or quality of studies. Because the objective of the guidance 
document is to help patients with established diagnosis of IBD, studies examining the 
role of diet in the etiology of IBD were categorized as EL very low. When possible, the 
review focused on the effect of diet on inflammation and symptoms; although, in some 
cases, data were only available for symptom control. Exclusive enteral nutrition, a known 
effective therapy for Crohn’s disease, was not addressed. All recommendations were 
made without consideration of other comorbid conditions that may influence choice of 
dietary patterns.  
 
Recommendations 
Consensus was achieved for all food types except pasteurized dairy consumption (Table 
1).  
 
Fruit & vegetables  
In CD it is prudent to recommend moderate to high consumption of fruits and vegetables (EL low). 
In patients with symptomatic or significant fibrostricturing disease, insoluble fiber intake should be 
restricted (EL very low)   
In UC, there is insufficient evidence to recommend any specific change or restriction in intake of 
fruit and vegetables. (EL very low)  
Fruits and vegetables are a diverse group of foods that generally have in common high 
fiber content. Fibers are undigested in the human small intestine, but the majority are 
fermented by bacterial enzymes within the colon, soluble fiber usually more rapidly than 
insoluble. Fermentation produces short chain fatty acids (SCFA), such as butyrate, that 
act as carbon and energy sources for the colonic epithelium. Decreased production of 
SCFA may occur in patients with active IBD.1  
Significant dietary restriction of fiber leads to greater bacterial consumption of colonic 
mucus which might contribute to inflammation.2 Specific soluble fibers, including plantain 
(banana) and broccoli pectins, reduce bacterial adherence and translocation by the 
epithelium;3 fiber may also serve as growth substrates for important SCFA-producing 
commensal bacteria.  
Epidemiological studies suggested that IBD patients consume less fruit and vegetables 
before disease onset, particularly for CD.4-6 In the prospective Nurses’ Health Study, 
women in the highest quintile for fruit fibre had approximately half the risk for subsequent 
Crohn’s disease development.6 However, in the European Prospective Investigation into 
Cancer and Nutrition (EPIC) study, no association between fiber intake and subsequent 
risk for CD or UC was found.7 Higher intake of fruits and vegetables has been 
associated with lower endoscopic activity of UC.8 An internet-based prospective study 
found that, among people with CD in remission, those in the highest quartile for fiber 
consumption were nearly half as likely to flare during 6 months follow-up, but there was 
no such association in UC.9  Patients with stricturing CD tend to avoid high fiber foods.  
A RCT of 2-years high fiber/low sugar diet showed no significant benefit or harm in 
adults with inactive or mildly active CD.10 In another trial among patients with CD, 
symptoms were worse with supplementation of inulin than placebo.11 
Data from additional studies are presented in Supplemental Table 1. 
 
Refined Sugar and Carbohydrates 
Recommendation 
In CD, there is insufficient evidence to recommend any specific change of intake of complex 
carbohydrates or refined sugars and fructose (EL low). It may be prudent to use a low FODMAP 
diet when for patients with persistent symptoms despite resolution of inflammation and absence 
of strictures (EL low).  
In UC, there is insufficient evidence to recommend any specific change of intake of complex 
carbohydrates or refined sugars and fructose (EL very low). It may be prudent to use a low 
FODMAP diet for patients with persistent symptoms despite resolution of inflammation (EL low). 
 
Several cross-sectional and case-control studies have observed increased sugar 
consumption in CD patients6, 12-20, although others suggest that this reflects a ‘modern 
lifestyle’ and is not necessarily causal. Evidence is lacking for UC. 
A randomized, controlled, multicenter study, including 352 patients with CD compared 
diets rich either in carbohydrate in its refined form or carbohydrate in its natural 
unrefined form without finding a significant difference in worsening clinical disease 
activity.10 Another randomized, controlled, multicenter dietary study, including 134 
patients with CD in remission21 who were instructed either to adhere to a low 
carbohydrate diet (of less than 84 g per day), mainly in a fiber-rich form or diet as usual. 
The intention-to-treat analysis showed no significant difference relative to the control 
group for prevention of relapse after one year; though patients appeared to have a 
symptomatic benefit during time that they adhered to the diet. A small uncontrolled study 
of the specific carbohydrate diet which excludes sucrose, fructose and other refined 
sugars demonstrated reductions in symptoms and mucosal inflammation as assessed by 
capsule endoscopy among children with CD.22  
There is no evidence of a role for altering the intake of slowly absorbed and non-
digestible short-chain carbohydrates (collectively known as FODMAPs) in modulating 
inflammatory activity of IBD. A placebo-controlled trials involving 15 g/day fructo-
oligosaccharides in patients with CD11 and challenge for 3 days with specific FODMAPs 
in patients with quiescent IBD did not significantly change inflammatory activity23, 
although fructans in both induced symptoms. Lowering of FODMAP intake in patients 
with symptomatic but quiescent IBD was associated with amelioration of functional 
gastrointestinal symptoms in comparison with those on a placebo diet without change in 
inflammatory status26, suggesting that these patients suffered from concomitant irritable 
bowel syndrome. Similar findings were noted in a feeding cross-over study27.  
 
Wheat and Gluten 
Recommendations  
In CD there is insufficient evidence to recommend restriction of wheat and gluten (EL Low) 
In UC there is insufficient evidence to recommend restriction of wheat and gluten (EL Low) 
 
 
Current evidence for restriction is based largely from 3 cross-sectional surveys where 
the prevalence of presumed gluten-associated symptoms was 5-28% in patients with 
IBD28-30 (Supplemental Table 2). Presumed gluten-associated symptoms were more 
common among those with stricturing or more severe CD and active disease.28, 30 In one 
study of gluten restriction, a high prevalence (65%) of patients observed improvements 
in one or more IBD symptoms, 38% described reduced frequency and severity of 
disease flares and strict dietary adherence was associated with marked improvement in 
fatigue.29  There are no data to indicate whether mucosal healing can be achieved via 
this dietary approach.  Since gluten co-exists in cereals with FODMAPs, improved 
symptoms might be related to reduced FODMAP intake.  
 
Gluten is hypothesized to modulate immune pathways in the small intestine,31  but the 
only supportive evidence comes from TNF knockout-mice.32 Other wheat-protein 
components, such as amylase trypsin inhibitors (ATIs), may drive intestinal 
inflammation.33  
Red Meat, Processed Meat, Poultry & Eggs 
Recommendations 
In CD, there is evidence that it is unnecessary to restrict moderate consumption of unprocessed 
red meat, lean chicken meat (breast of chicken) and eggs (EL high).  
 In UC, it is prudent to reduce intake of red and processed meat (EL low).  
 
In a systematic review, 6 of 8 studies demonstrated an association between red meat 
intake and incidence or worsening of UC, two of which were statistically significant. In a 
prospective French inception cohort of 67,581 people,34 high animal protein intake was 
associated with a significantly increased risk of IBD, CD and UC  for the highest versus 
the lowest tertile of consumption (IBD overall HR 3.03, 95% CI 1.45 – 6.34, Ptrend = 0.005 
corrected for energy intake). Red meat intake was also associated with a greater than 5-
fold increase in the odds of a UC relapse in one prospective study35, but not in a recent 
smaller study that combined patients with CD and UC.36 A cross-sectional study in 103 
adults in remission37  also demonstrated a higher risk of relapse with an OR of 3.6 for 
the highest quartile of red meat consumption. However, a more recent study38 in 412 
adults with UC in remission and followed until relapse demonstrated that the intake of 
fats and specifically myristic acid was associated with flares, while processed meats 
were not. Myristic acid is a saturated fatty acid enriched in coconut oils, dairy fats but 
also in beef from grain fed cattle.39  Red meat was not assessed independently in this 
study.  
One prospective clinical trial comparing high versus low levels of consumption of red 
meat or processed meat has been conducted in adults with CD.40 Relapse rates did not 
differ between the two treatment groups. Recently published clinical trials involving a diet 
that required daily consumption of chicken breast and two eggs/day for 12 weeks was 
associated with high rates of remission in active CD41-43 suggesting that these products 
are safe to consume in moderation as a source of protein in CD. A summary of studies 




Consensus was not obtained for CD or UC for pasteurized dairy products. Consensus was obtained 
that unpasteurized dairy products should not be consumed.  
Dairy products include a wide variety of natural and processed foods which may vary 
greatly from one product to another due to differences in processing, fat content and 
food additives. Most contain lactose, but some do not. In the developed world, dairy 
products often contain significant amounts of emulsifiers, carrageenans and other 
thickening agents which are subsequently reviewed. This complicated the discussion 
and led to lack of consensus. 
Exposure to casein in a DSS mouse model of UC led to increased severity of colitis. 
However human data are lacking to confirm this experiment.44 In the prospective EPIC 
study, there were no statistically significant trends between the intake of dairy products 
and the development of CD or UC.45 (Supplemental Table 4).  
Prospective cohort studies report a prevalence of lactase deficiency of 40-50% in CD 
and 27-40% in UC, both higher than in healthy controls.46, 47  A recent systematic review 
and meta-analysis of 17 studies reported an odds ratio compared to controls for lactose 
malabsorption in CD patients of 2.29 (1.09–4.80; p=0.03) and in UC of 1.14 (0.69–1.86; 
p = 0.62).48 Therefore, it appears that lactose malabsorption is more common in patients 
with CD than healthy controls.  
Baseline dairy intake was not associated with risk of disease flare in adults with 
quiescent UC and eliminating dairy in a small randomized trial had no apparent benefit 
on pediatric UC patients.35, 49 
 
Unpasteurized milk should be avoided by all patients with inflammatory bowel disease 




In CD, it is prudent to reduce exposure to saturated fats (EL low) and avoid trans fat (EL very low).  
In UC, it is prudent to reduce consumption of myristic acid (palm oil, coconut oil, dairy fats) (EL 
low).  It is prudent to increase dietary consumption of omega-3-fatty acids (DHA and EPA) from 
marine fish (EL low), but not from supplements (EL high). It is prudent to avoid trans fat (EL very 
low).  
Total fat  
In a prospective cohort of adult  patients with UC, increased meat consumption, 
especially processed meats, and sulfur were associated with a higher risk of relapse.35  
The highest tertile of consumption of fat also had a higher risk for flare than the medium 
tertile of fat consumption (OR 2.52 (1.06–5.97)).Total fat intake is associated with active 
CD in some, but not all studies.50, 51  Studies of enteral nutrition formulas show no 
consistent variation in efficacy for CD based on total fat content.52  
Saturated Fats  
Among 412 UC patients in clinical remission on mesalamine, only higher intake of 
myristic acid, a saturated fatty acid found in coconut oil, palm oil and dairy products, was 
independently associated with an increased odds of flare within 1 year (OR 3.01, CI 
1.17-7.74), with a dose-response effect.38   
Unsaturated Fats 
Monounsaturated Fatty Acids (MUFAs) 
Monounsaturated fat, including palmitoleic acid and oleic acid, is found in plant-based 
oils including olive oil, as well as in macadamia nuts, beef tallow and lard.  Enteral 
nutrition supplemented with either oleic acid (a MUFA) or linoleic acid (an n6 PUFA) 
found that linoleic acid had higher remission rates in CD although neither was as 
efficacious as steroids for clinical remission.53  However this was only one study. Studies 
with the Crohn’s Disease Exclusion Diet allow unlimited olive oil rich in MUFA and this 
diet was associated with clinical remission and reduction in inflammation.39 UC patients 
treated with olive oil derivatives had reduction in peripheral and intestinal T cell 
activation and interferon-γ production.54   
 
Polyunsaturated Fatty Acids (PUFAs) 
Foods rich in n-3 PUFA include marine fish like salmon, mackerel and herring, as well as 
certain nuts and seeds (such as walnuts, flax, hemp and chia seeds). A small study 
found a non-significant decrease in disease activity in UC patients who consumed 600 
mg of Atlantic salmon weekly for 8 weeks.55 In one study, patients whose diet 
approximated a ratio of n-3:n-6 closer to 1, were more likely to be in remission than 
those with a higher ratio of  n-6 foods56. Higher dietary intake of α-linolenic acid (a 
precursor of long-chain n-3 PUFA) was associated with increased risk of UC relapse 
whereas total n-3 PUFA without supplementation was protective.   
In a meta-analysis of three trials looking at maintenance of remission in UC with n-3 
PUFA supplementation, there was no added benefit to supplementation (RR for 
relapse=1.02 (CI 0.51-2.03).57  Similarly, a systematic review looking at n-3 PUFA 
supplementation for treatment of any IBD found no consistent benefit for prevention of 
UC relapse among 4 available studies.58  
In CD, two large placebo-controlled multicenter RCTs using 4g/day of supplemental n-3 
PUFA found no efficacy for the prevention of relapse.59  However, a meta-analysis of six 
heterogeneous trials with 1039 patients showed a small benefit of supplementation for 
reduction of relapse (RR of relapse of 0.77, CI 0.61-0.98) (I2=58.4%, p=0.03).57 
Therefore, current evidence is inconclusive for n-3 PUFAs (like fish oil) in IBD. By 
contrast, foods naturally high in n-3 PUFAs and low in n-6 PUFAs may be beneficial 
although evidence is weak. 
 
Trans-Fats (unsaturated fat) 
A case-control study comparing 62 newly diagnosed UC patients to 124 healthy controls 
found higher consumption of total fats and trans-fats to be significantly associated with 
increased risk of UC.60 In a prospective cohort, higher long-term intake of trans fats 
demonstrated a trend towards increased incidence of UC.61 Moreover, trans-fats are 
believed to have other deleterious health effects. Though data in humans regarding the 
effect of trans- fat upon inflammation is lacking, due the deleterious nature we 




In CD, there is insufficient evidence to recommend changes in low level alcohol consumption (EL 
low).  
In UC, there is insufficient evidence to recommend changes in low level alcohol consumption (EL 
low).  
 
Alcohol use prior to a diagnosis of IBD 
A meta-analysis of 9 UC studies did not find a significant association (RR=0.95 (95% CI, 
0.65-1.39) with risk for UC comparing the highest to the lowest alcohol intake.62  In CD, 
one study reported that alcohol (≥one drink/week) was not associated with new onset 
disease,63 while another reported increased alcohol consumption (P=0.009) in recently 
diagnosed CD patients compared to healthy controls.64 The EPIC study found no 
association between alcohol consumption prior to recruitment and subsequent UC or CD 
development.65   
Triggering flares  
In a small prospective cohort study, UC patients in the top tertile for alcohol consumption 
had a 2.7-fold higher odds of flare compared to the bottom tertile (Supplemental Table 
5).35 In contrast, a daily glass of red wine was associated with a reduction in fecal 
calprotectin in inactive IBD patients.66  
In an internet-based survey of 2329 patients with IBD, alcohol consumption was 
identified as a potential trigger of worsening gastrointestinal symptoms.67 However, 
inactive IBD patients consume alcohol at rates similar to that of the general US 
population, though 75% reported its impact on gastrointestinal symptoms.68 Of CD 
patients who consumed alcohol, 40% reported symptom worsening while 41% did not; 
there was no association with a particular type of alcoholic beverage.   
 
Maltodextrin and Artificial Sweeteners 
Recommendations 
In CD, it may be prudent to limit intake of maltodextrin-containing foods and artificial sweeteners 
(EL very low).  
In UC, it may be prudent to limit intake of maltodextrin-containing foods and artificial sweeteners 
(EL very low).  
  
In vitro and in vivo studies have linked food additives, artificial sweeteners and their 
components to IBD.69-71 Maltodextrin is a hydrolyzed starch and a common dietary 
polysaccharide used as a thickener for foods and confections.72 Splenda®, an artificial 
sweetener, is comprised of 1% sucralose and ~99% maltodextrin as a filler.  
Increased consumption of artificial sweeteners over the past few decades parallels the 
increased incidence of IBD cases.73 This trend is similar for rising maltodextrin 
availability within the American diet.74 Several epidemiologic studies correlated 
consumption of added sweeteners and sugar in soft drinks with an increased IBD risk 
(Supplemental Table 6).75-77  
In animal models, consumption of artificial sweeteners has been shown to increase 
inflammatory markers in the gastrointestinal system (Supplemental Table 7). In vitro 
studies of GI tissue exposed to maltodextrin observed enhanced cellular biofilm 
formation of CD-associated E. coli strains (AIEC), which adhered to intestinal epithelial 
cells and mimicked dense biofilm formations found in the gut of CD patients.70 MalX 
(maltose/maltodextrin binding protein gene) is a gene central to maltodextrin 
metabolism. Both studies of Splenda® supplementation in SAMP mice and in vitro 
culturing of GI tissue with maltodextrin observed an increase in bacterial malX gene 
expression in the ileal mucosa obtained from CD patients and murine model of CD 
relative to healthy controls (p<0.0175, p<0.03).69, 70 This association links maltodextrin to 
CD pathogenesis by suggesting that its metabolism promotes the colonization and 
translocation of these CD-associated bacteria. Finally, common artificial sweeteners and 
maltodextrin induced alterations in the mouse gut microbiota that are similar to those 
observed in IBD.69, 78-81  
It is notable that maltodextrin is found in many nutritional supplements, including some 
used for exclusive enteral nutrition which has been demonstrated to be an effective 
therapy. Thus, while there is theoretical and animal model data to support avoidance of 
maltodextrin among patients consuming a whole food diet, these data or 
recommendations should not dissuade the use of exclusive enteral nutrition in 
appropriate situations.  
Emulsifiers and Thickeners 
Recommendations 
In CD, may be prudent to reduce intake of processed foods that contain carrageenan, 
carboxymethylcellulouse and polysorbate-80 (EL very low).  
In UC, may be prudent to reduce intake of processed foods that contain carrageenan, 
carboxymethylcellulouse and polysorbate-80 (EL very low).  
 
Manufacturers add emulsifiers to processed foods to improve food texture and quality.82, 
83 The most extensively used emulsifier, lecithin, is derived from egg or soya, and 
consists of varying proportions of phosphatidyl choline, ethanolamine or inositol.84  Other 
emulsifiers and thickeners include carboxymethylcellulose (CMC), carrageenan, and 
polysorbate-80 (P80). Epidemiological data supports an association between some 
emulsifier exposures and IBD incidence84-86   
A carrageenan-free diet supplemented with food-grade carrageenan (n=5) or placebo 
capsules (n=7) was administered to subjects with quiescent UC.87 Three carrageenan-
exposed but no control subjects relapsed. .  
Tobacman 88 reviewed 45 studies on the health effects of degraded and un-degraded 
carrageenan in rats, mice, guinea pigs, rhesus monkeys, and rabbits. Study durations 
and carrageenan doses ranged from 1 day to 1 year and 0.1% to 10%, respectively. 
Carrageenan exposure led to intestinal lesions, neoplasia, ulceration, carrageenan 
accumulation in intestinal lymph nodes, stricture and UC-like inflammatory changes. 
Ulceration correlated with dose, duration of carrageenan exposure. Whether the doses 
used are relevant in humans is questionable.  
Effects of carrageenan exposure also include increased occult blood in stool,89 mucosal 
ulcerations,90, 91 serum inflammatory makers,91, 92 small bowel and colonic lesions,93 
reduction in crypts number and length,94, 95 inflammatory cell infiltrate90, 91 and epithelial 
damage 94, 96 (Supplemental Table 8).  
Two emulsifiers or thickeners (Polysorbate 80 and carboxymethylcellulose) have been 
evaluated in animal models. P80 was been shown to increase intestinal permeability in 
mice97. Chassaing et al. demonstrated that addition of CMC and P80 to drinking water 
can reduce mucus thickness, elevate levels of fecal lipocalin2 and can induce colitis in 
IL-10 knockout (KO) mice.98  
Hydrolysed carrageenan induced IBD in piglets, with associated increases in 
Proteobacteria and decreases in Firmicutes, Actinobacteria and Bacteroidetes.99  In wild 
type and colitis-susceptible mice exposed to CMC and P80, microbial diversity 
decreased and Akkermansia muciniphila and Proteobacteria increased.100 Transplanting 
cecal content from emulsifier-treated to germ free mice caused microbial epithelium 
encroachment and low-grade inflammation, mediated by altered bacterial composition 
and elevated fecal lipopolysaccharide (LPS) and flagellin.  
Recent studies in animal models of IBD also indicated that various EDTA compounds 
(Ca-EDTA, Na-EDTA, Fe-EDTA) as used for food preservation or iron fortification have 
proinflammatory and proneoplastic effects.101  
Nanoparticles and Sulfites 
Recommendations 
In CD, it may be prudent to reduce exposure to processed foods containing titanium dioxide and 
sulfites (EL low).  
In UC, it may be prudent to reduce exposure to processed foods containing titanium dioxide and 
sulfites (EL very low).  
Sulfites are used to preserve wine and beer, commercial lemon juice and vinegars, dried 
or canned fruits and processed meats. When used as preservatives, they generally are 
not nanoparticles, but can be when used in other formulations such as iron sulfite. In IL-
10 KO mice, dairy fat induced dysbiosis and  colitis via a bloom of sulfite-reducing 
bacteria Bilophila Wadsworthia.24 Bacteria such as Bilophila are potential intestinal 
pathobionts that may grow with a high fat diet or high dairy fat diet .An exogenous 
source of sulphites from food could theoretically have the same effect; whether 
exogenous sulfites would exert the same effect was not tested. 
Nanoparticles such as titanium dioxide (Ti02) and aluminum silicates (AlSi) are used as 
food additives to color, coat or preserve food. Nanoparticles are highly stable and 
resistant to degradation. TiO2 is a white, crystalline powder, used as a pigment in 
confectionery, white sauces, dressings, nondairy creamers, and toothpaste.102 AlSi is 
added to salt and other powdered foods to prevent clumping. 
In mice, oral administration results in Ti02 accumulation in intestinal epithelial and 
immune cells with activation of the NLRP3 inflammasome.103 Oral administration of TiO2 
nanoparticles also enhances intestinal inflammation in a murine model of colitis.103 
Similar findings have been reported for dietary aluminum intake, which also impairs 
intestinal barrier function.104  
Ti02 is normally trapped in the intestinal mucus layer,105 although systemic absorption 
has been reported after supra-physiological intake in volunteers with normal intestinal 
permeability.106 Nanoparticles (mostly TiO2 and AlSi) have been identified within 
phagocytes located in intestinal lymphoid aggregates in IBD patients. In addition, 
patients with active UC have higher serum titanium levels than UC patients in remission 
and controls.103 
Two dietary intervention studies have assessed the impact of TiO2 on CD 
(Supplemental Table 9). A pilot study randomized 20 patients with active ileal or ileo-
colonic disease (CDAI > 150) off immunosuppressive therapy to a TiO2/AlSi-restricted 
diet or a control diet for 4 months.107 A significant reduction in mean CDAI was seen in 
the intervention group only, with seven patients on the intervention diet (70%) compared 
to 0 on the control diet (0%) achieving clinical remission (CDAI < 150).107 A subsequent 
16-week multicenter study randomized 83 patents with active CD to a low or normal 
nanoparticle diet, indicated no differences in remission or clinical response between 
groups.108 Of note, patients in the pilot study followed a more restrictive diet, avoiding all 
processed foods.  Given the first positive study combined with the animal models, the 
level of evidence for CD was rated as low.  
 
Discussion 
This dietary guidance consensus document from the IOIBD is based on the best 
available evidence to date. For patients with CD, we recommend regular intake of fruits 
and vegetables (in the absence of symptomatic strictures) and reduced intake of 
saturated-, trans-, and dairy-fat, additives such as polysorbate 80 and 
carboxymethylcellulose, processed dairy or foods  rich in maltodextrins, artificial 
sweeteners containing sucralose or saccharine, and processed food containing 
nanoparticles. For patients with UC, we recommend increased consumption of natural 
sources of omega-3 fatty acids (e.g. from wild salmon and other natural sources, not 
from supplements). The foods that patients with UC should avoid are similar to CD with 
the possible addition of red and processed meat (Figure). There was insufficient 
evidence to recommend changes in the consumption of fruits, or vegetables for patients 
with UC. For patients with either CD or UC, there was insufficient evidence to 
recommend changes in consumption of wheat or gluten, poultry, alcoholic beverages 
other than binge drinking (in the absence of other liver disease), and refined sugars. The 
committee was unable to come to a consensus on pasteurized dairy products. None of 
these recommendations are meant to exclude the role of nutritional assessment for 
malnutrition and correction of deficiencies when needed. Our main recommendations 
are aimed at reducing both symptoms and inflammation. For patients with persistent 
symptoms despite resolution of inflammation and absence of strictures, a low FODMAP 
or lactose-free diet may improve symptoms.  
We acknowledge several limitations of this consensus document from the nutrition 
cluster of IOIBD. The recommendations were the consensus opinion of a relatively small 
group of IBD clinicians and scientists with expertise in the field. Dietary studies are 
particularly challenging to implement and therefore may be subject to various forms of 
bias.109 For example, blinding study participants to treatment arm is difficult. When a 
food is eliminated, it is necessary to replace the calories usually obtained from this food 
with a different food. Sample sizes have historically been small, and therefore the 
studies were often under powered. Additionally, several of the recommendations are 
based largely on the results of experiments in animals, such as the effect of thickeners, 
emulsifiers, and maltodextrin. Moreover, some of these are in contrast to the known 
efficacy of exclusive enteral nutrition. For some of the members, the vote to reduce 
intake may be in part because these food additives are not believed to have nutritional 
value. However, we did not quantify this in the process of voting. Finally, these 
recommendations may require change as new information becomes available.  
There are several dietary patterns that are commonly recommended for patients with 
IBD (e.g. Mediterranean diet, Specific Carbohydrate Diet, Crohn’s Disease Exclusion 
Diet). At the outset, we hoped to make recommendations regarding specific dietary 
patterns. However, the lack of RCTs testing these dietary patterns precluded coming to 
strong recommendations. As such, we limited our recommendations to components of 
the diet. Nonetheless, several trials have just completed or are ongoing and may allow 
for stronger recommendations in the near future. 
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Insufficient evidence to 
recommend specific dietary 
changes (very low, 100%) 
Prudent to increase 
exposure (low, 84.6%) 
Epidemiology 
Clinical studies 
Reduce insoluble fiber if 
stricture present (Evidence 
level very low) 
Vegetables 
  
Insufficient evidence to 
recommend any specific 
changes (very low, 100%) 
Prudent to Increase 
exposure (low, 84.6%) 
Epidemiology 
Clinical studies 
Reduce insoluble fiber if 
stricture present (Evidence 




Insufficient evidence to 
recommend any specific 
changes in refined sugar or 
complex carbohydrate intake 
(low, 92.3%) 
Insufficient evidence to 
recommend specific 






Insufficient evidence to 
recommend restriction of 
wheat and gluten (low, 
100%) 
Insufficient evidence to 
recommend restriction of 




Gluten has been associated 






Prudent to reduce intake of 
red and processed meat 
(low, 100%) 
 
Insufficient evidence to 
recommend restriction of 





Poultry Insufficient evidence to 
recommend dietary changes 
(low, 100%) 
Insufficient evidence to 
recommend restriction of 
intake (high, 100%) 
Epidemiology Lean chicken breast is a low 
animal fat & low taurine source 
of protein and is allowed in the 




Unable to reach consensus 
(92.3%) 
 




Dairy products encompass a 
wide range of products. 
Lactase deficiency and lactose 
intolerance is common among 
patients with IBD. 
Prudent to reduce dairy fat and 
processed dairy rich in 
maltodextrins and emulsifiers 
Unpasteurized 
dairy products 
Prudent to avoid in all 
patients (100%) 




Avoid infections that can result 
from consumption of 
unpasteurized dairy products 
Dietary Fats 
 
Prudent to reduce 
consumption of myristic 
acid (palm oil, coconut oil, 
dairy fats (low, 100%)  
 
Prudent to avoid trans-fat 
(very low, 100%)  
Prudent to increase dietary 
consumption of omega-3-
fatty acids (DHA and EPA) 
from marine fish (low) but 
not from dietary 
supplements (high, 100%) 
Prudent to reduce 
exposure to saturated fats 
(GRADE low, 100%) and 







Myristic acid linked to UC is 
found in palm and coconut oil, 
dairy fat and meat from grain 
fed as opposed to grass fed 
animals 
 
Natural omega-3 fatty acids are 





Insufficient evidence to 
recommend changes in low 
level alcohol consumption 
(low, 100%) 
Insufficient evidence to 
recommend changes in low 
level alcohol consumption 
(low, 100%) 
Epidemiology A trial of avoidance alcohols 
containing high levels of 
sulfites (i.e. beer and wine) is 
















It may be prudent to limit 
intake of maltodextrin-
containing foods and 
artificial sweeteners (very 
low, 92.3%)  
It may be prudent to limit 
intake of maltodextrin-
containing foods and 








It may be prudent to limit 
intake of 
carboxymethylcellulos and 
polysorbate-80 (very low, 
92.3%)  
It may be prudent to limit 
intake of 
carboxymethylcellulos and 




E433 – polysorbate 80 
E466 - corboxymethylcellulose 
Carrageenans 
 
It may prudent to reduce 
intake of processed foods 
containing carageenans 
(very low, 92.3%)  
It may prudent to reduce 
intake of processed foods 
containing carageenans 
(very low, 92.3%) 
Epidemiology 
Animal models 
One very small 
RCT 
Found in dairy-based desserts, 





It may prudent to reduce 
intake of processed foods 
which contain titanium 
It may prudent to reduce 
intake of processed foods 
which contain titanium 
Clinical trial in CD 
Animal models 
and translational 
The inconsistent results of the 
two clinical trials of low 
nanoparticle diets led to a 
 dioxide and sulphites (very 
low, 92.3%) 
dioxide and sulphites (low, 
92.3%) 
studies in UC downgrading of the evidence 
CD – Crohn’s disease; UC – ulcerative colitis 
BLUE= a recommendation to increase consumption 
RED= a recommendation to reduce consumption 
 
  
Supplemental Table 1: Interventional studies of fiber, inulin, and low FODMAP diets 
Author 
(year) 









352 Inactive or mildly 
active CD 
Relapse over 2 years defined 
by need for alternative 
treatment 
No difference between high fiber, low 







103 Active CD 
(CDAI>/=220) 
Response (CDAI fall of 
>/=70) by week 4 
Supplementation with 15g/day fructo-
oligosaccharides (including inulin) 
caused non-significant  worsening of 
response rate and increased 
withdrawal with more flatulence (p= 
0.004) and abdominal pain (p= 0.048) 
Prince 
(2016) 






88 39 CD, 38 UC, 11 
IBD-U 
Satisfactory relief of 
functional gut symptoms 
(FGS) by follow-up (mean 
2.6months) 
78% satisfactory relief of symptoms by 











32 18 UC, 14 CD IBD in remission, previous 
functional symptoms that 
had responded to low-
FODMAP diet 
Challenge with 12g/day of fructans for 
3 days but not 6g/day of galacto-
oligosaccharides, or 6g/day of sorbitol 
or 12 g/day of glucose (placebo) 
reduced proportion of patients free 
from functional symptoms (62% vs 
90%, p = 0.033) 
CD – Crohn’s disease 
 
  
Supplemental Table 2. Cross-sectional surveys of patients regarding use of gluten free diets and patient reported outcomes 












145 Combination of CD 
(68% with active 
disease, 32% 
quiescent) and UC 







Use of gluten-free diets 
(GFD) 
 
Prevalence of self-reported NCGS was 28% 
in IBD patients (29% Crohns, 27% UC) 
None had diagnosed celiac disease 
19% IBD patients had tried GFD but only 9% 
were still adhering to the diet 
Abdominal pain, discomfort, bloating, 
diarrhea, fatigue and headaches were 
symptoms associated with gluten ingestion 
in IBD 
Patients with Crohn’s and NCGS tended to 
have stricturing and more severe disease, 











Use and adherence to 
GFD 
Symptomatic 
improvement on GFD 
5% patients with IBD had reported NCGS 
whereas 0.6% had concurrent coeliac 
diagnosis  
19% had tried GFD and 8% were still 
following the diet 
66% reported improvement of 
gastrointestinal symptoms  
38% also reported a decrease in frequency 
and severity of flares 
Strict adherence to a GFD was associated 




102 54% Crohn’s, 45% 





20% had self-reported gluten sensitivity 
(Excluding those with concurrent celiac 
disease) 







No differences in reported GI or extra-
intestinal symptoms in those with or 
without gluten sensitivity 
Presence of stenosis in Crohn’s, recent flare 
and dermatological symptoms were 
associated with gluten sensitivity 
Supplemental Table 3. Clinical studies of meat consumption in IBD 



























Adult patients in 
remission 
on a biannual 
survey and who 
reported 
consumption of 
red meat at 
least once 





 Arm A- a minimum 
of 2 servings/week 
or Arm B- not more 
than 1 serving per 
month of red or 
processed meat for 
48 weeks. 
Adherence to the high meat 
diet, determined by % 
weeks consuming 2+ 
servings of red or processed 
meat, was 98.5% compared 
to 57% adherence to the low 
meat diet. At least a mild 
relapse occurred in 59% of 
patients during the study. 
There were no significant 
differences in time to overall 
(Fig 1, p=0.61) or 
moderate/severe (Fig 2, 
p=0.50) relapse. 
Prévost 









Women living in 
France, aged 40 





Women aged 40 – 65 








every 2 years.   
77/67,581 cases of IBD  
High total protein intake, 
specifically animal protein 
was associated with a 
significantly increased risk of 
IBD, (HR 3rd Vs 1st tertile 
3.31 (1.41 – 7.77),  P = 
0.007), and 3.03 
(1.45 – 6.34) ( P = 0.005) for 
total and animal protein, 
respectively). 
High consumption of meat 
or fish but not of eggs or 
dairy products was 
associated with IBD risk 












Determine the effect 
of habitual diet on 
Relapse. Relapse was 
defined using SCCAI, 
. Nutrient intake was 
assessed using 
a FFQ follow up of 1 
year 
52% of patients relapsed. 
Consumption of meat (OR) 
3.2 95% (CI) 1.3–7.8)), 
particularly red and 
processed meat (OR 5.19 
(95% CI 2.1–12.9)), in the 
top tertile of intake 
increased the likelihood of 
relapse compared with the 
bottom tertile of intake. 








 50 with active 
disease and 53 
in remission, 
divided by their 
calprotectin 
level 
Meat Cross sectional 
study, evaluating 
food intake using 
FFQ and disease 
activity by 
calprotectin 
meat intake showed a 
positive effect on  disease 
relapse, the highest quartile 
for meat consumption 
coinciding with a higher risk 
of active disease (OR 3.61, 




























enrollment and were 
followed for 12 
months 
Forty-five patients (11%) 
had a UC relapse within 1 
year of study enrollment. 
Processed meat, was not 
associated with an increased 
risk of flare. 
















new cases of 
IBD (41 
ulcerative 
colitis, 42 CD) 
and 160 healthy 
controls 
red meat Portions per week of 
34 foods and 
beverages before 
onset of symptoms 
were recorded 
using a validated 
questionnaire 
Changes in dietary habits, 
due to the presence of 
symptoms, were reported 
by 38.6%. high consumption 
of red meat 
(OR = 7.8) (95%CI: 1.61–




















 Vegetarian diet protective 
for UC OR 0.329, 95% CI 
0.27–0.39 
not for CD 





   Consumption of a diet high 
in red meat increased 
DSS-induced colitis as 
evidenced by higher disease 
activity and 
histopathological scores. 
Addition of resistant starch  
to the red 
meat diet abolished the  
effect in acute DSS-induced 
colitis. 
Opstelten  JL et 
al  

















FFQ at enrolment 
and follow up for 
relapse 
Higher intake of animal 
protein and carbohydrates 
among patients. No 
increased risk of relapse by 






















CDED arm received 
150-200 gram 
chicken breast and 2 
eggs every for 12 
weeks 
EEN arm received 
free diet 
CDED arm superior 
remission and reduction in 
inflammation by week 12 
(CDED) 
 
CD – Crohn’s disease   
Supplemental Table 4. Clinical studies of dairy consumption in IBD 











401,326 Habitual diet of 
healthy men and 




110 incident cases 
CD and 244 UC 





development  of 
IBD  
Validated food frequency questionnaires 
completed within healthy individuals over 
12 European centers suggest no relationship 
between quartiles of dairy consumption and 
development of IBD.   Comapred to non-
consumers, those that consumed mild had a 
reduced risk of CD (OR 0.30, 95% CI, 0.13-
0.65) 
Barrett (2009) Prospective cohort 
study 








(91), UC (56), 
Functional GI 











between 2 x 
consecutive 15 
minute intervals.   
 
Lactose malabsorption was most common 
in CD (42%) and UC (40%).  Lactose 
malabsorption was more frequent in 
patients with Ileal CD than those with 
Ileocolonic (39% P= 0.058).   
 
 
Eadala (2011) Prospective cohort 
study 
165 Breath and 
genotype testing 
for prevalence of 
lactose intolerance 
between CD (n-70), 
RT-PCR testing 




Genotype CC is associated with low levels of 
lactase in duodenal biopsies, CT slightly 
greater and TT genotype represents higher 
lactase concentrations.  
None of the healthy volunteers had CC 
UC (n-95) and 
healthy control (n-
30). Male and 
female Caucasian 
adults mean age 
47years. Disease in 
remission. 
consumption of 




and genotype.   
genome and none tested positive for 
hydrogen or methane breath testing.  
7% of IBD patients had CC genome 
suggesting no absolute association IBD and 
lactose intolerance.  The effects of hydrogen 
breath testing suggested 26% UC and 49% 
of CD versus 0% of the healthy control.  
65% of UC and 76% CD patients with 
hydrogen levels >20ppm reported GI 
symptoms up to 48hrs post ingestion of 50g 
lactose.   
Lopes (2014) Cross sectional 
dietary 
questionnaire 












FFQ and photographs to demonstrate 
portion sized were used to estimate dairy 
intake.  
Bloating and bleeding were the main 
symptoms reported although disease 
activity was not discussed. 64.7% of patients 
restricted dairy produce following diagnosis, 
45.5% due to exacerbation of symptoms, 
36.4% advised by health professional.  80% 
of patients had seen a Nutritionist.  
Ethnicity had not been documented; greater 
prevalence of lactose intolerance in non-
Caucasian population groups may be a 






Secondary analysis  165 Caucasian adults 







diary intake and 
symptom profile 
reassessed at 6 
month intervals.  
Dairy products had no effect on self-
reported CD symptoms for most people. 
Dairy products with a high fat content were 
most frequently reported to worsen 
perceived CD symptoms 
 
CD – Crohn’s disease; UC – ulcerative colitis 
  
Supplemental Table 5. Studies of alcohol in IBD 
Author (year) Study design 
(country) 




Key findings  
Cohen (2013)  Cross sectional 
survey (USA)  
6,768 Mix of CD and UC 
patients with or 
without ostomy or 
pouch.  
Association 




Alcohol was more frequently 
reported to worsen symptoms 
within most disease 
categories.  
Swanson (2010) Cross sectional 
survey (USA) 
129 Mix of CD (52), UC 
(38), and IBS (39) 
patients.   
Patterns of alcohol 
consumption and 
its association with 
GI symptoms. 
Inactive IBD patients drink 
alcohol similar to general 
population.  
 
Inactive IBD drinkers more 
likely to report worsening GI 
symptoms than current IBS 
drinkers.  






Mix of inactive UC 
patients (8), inactive 
CD patients (6), and 
healthy controls (7). 
Effect of daily 
moderate red wine 
consumption for 1 
week on intestinal 
permeability and 
stool calprotectin.  
Moderate alcohol did not 
change clinical disease activity 
scores (UCAI, CDAI) or CRP but 
decreased stool calprotectin 
and increased intestinal 





cross over, open 
label study 
(Denmark) 
32 Inactive CD patients 
(20) and healthy 
controls (12).  
Effect of ethanol 
and sugar content 
in five different 
alcohol drinks on 
abdominal 
discomfort. 
Higher plasma AUC for 
glucose and more pronounced 
abdominal discomfort in CD 
patients following intake of 
alcohol drinks with higher 
sugar concentration.  
 
No difference in AUC for 
ethanol between CD patients 
and controls. 
Zutshi  Survey of registry  4,464 (1,220 CD patients seen in What patients think Alcohol increased symptoms 
(2007) (USA) analyzed)  a digestive disease 
center between 
2002 and 2007. 
is relevant to their 
symptoms and 
helps them cope. 
in 40%.while 41% did not have 
any change in their 
symptoms. There was no 
particular type of alcoholic 
beverage that affected 
symptoms. 










factors and UC 
relapse risk. 
Alcohol increased likelihood 








288,055 57,611 inpatients 
with new onset 
alcohol intoxication 




between AI and IBD 
development risk. 
AI cohort had increased risk of 
IBD (HR 3.17, 95% CI 2.19- 
4.58). 
 
Mean (SD) between 
hospitalization for AI and IBD 






2616 1308 UC patients 
and 1308 matched 
controls. 
Risk factors for UC 
development. 
Alcoholic drinkers were at 
higher risk of developing UC 
(light drinkers: OR 1.264, 95% 
CI 1.073-1.490, heavy 












factors and UC 
development risk. 
No association. 
Samuelsson (1991) Case-control 
study  
(Sweden) 








and medical history 
No association between UC 















No association between UC 
development and alcohol. 






384 UC patients 
who received 
financial aid for 
treatment of their 
disease and 384 








Usual consumption of alcohol 
reduced the risk of UC 
compared with less frequent 
use (OR 0.57, 95% CI 0.37-
0.86). 
Porter (2017) Prospective 
cohort study (The 
millennium 







Incident IBD was 
identified from 
medical encounters 
from 2001 to 2009 
or by self-report. 
 
58 and 49, new 
onset cases 
identified for CD 
and UC, 
respectively.  
Incidence and risk 
factors of IBD in a 
US military 
population. 
23.2 and 21.9 diagnoses per 
100000 person-years, 
respectively, for CD and UC. 
 
Moderate alcohol 
consumption was associated 
with lower UC risk (aHR 0.4, 











209 UC patients and 
209 matched 
controls of a pre-







Current alcohol users had a 
lower risk of UC compared to 
non-users. Risk of disease 
decreased as number of 
alcoholic drinks consumed per 













factors and UC 
Drinking alcohol once per 
week showed a slight 
protective effect.  
of European 
descent 
development risk.  
Octoratou (2012)  Questionnaire  
(Greece) 
96 28 newly diagnosed 
CD patients (2-4 
weeks), 30 patients 
with established 
diagnoses of CD (2 -
11 years), and 38 
matched controls.   
Assess food 
consumption in CD 
patients exactly at 
the time of 
diagnosis and 
identify dietary 
constituents as risk 
factors for 
development of CD.  
Increased consumption of 
alcoholic drinks (P = 0.009) in 
recently diagnosed CD 
patients in comparison with 
healthy controls. 

















study within the 
EPIC cohort study.  
 
Assess the role of 
pre-disease alcohol 
consumption on 
the risk of 
developing UC or 
CD. 
There was no evidence of 
associations between alcohol 
use and the odds of 
developing either UC or CD. 












41,810 IBD patients, 
18,695 UC patients, 
and 24,059 CD 
patients. 
Assess alcohol’s 
role in exacerbating 
UC flare and/or 
onset. 
IBD patients with documented 
history of alcohol use may 
have an increased risk of 
infections as well as require 
more diagnostic and 
therapeutic procedures. 
CD – Crohn’s disease 
Supplemental Table 6. Studies of artificial sweeteners in humans. 






256 with UC and 




with controls  
 
UC: median age 51.5 
years at diagnosis 
(CD – 50.3 years), 
61% female (CD – 
73%), range: 20-80 
years old, 3.8 years 
between entry into 
cohort and diagnosis 




Positive association between “high 
sugar and soft drink” dietary pattern 
and UC risk (IRR for fifth versus first 
quintile = 1.31 [0.85-2.02]; Ptrend = 
0.05) only if also low vegetable 






108 with UC, 
126 with CD, 
211 control 
Ages 15-34, within 3 
years of diagnosis, 
each case matched 
with control of same 





Positive association between 
consumption of sugars and sweeteners 
and CD risk (OR 2.12; 95% CI, 1.08 
to 4.17), UC risk not significant  
Hansen (2011) 
 
Case-control study 123 with CD, 





age of IBD patients 




High sugar intake positively 
associated with IBD, more significant 
odds for CD (CD: OR 3.50; 95% CI, 
1.73-7.07) (UC: OR 1.68; 95% CI, 
0.96-2.97), confounding factor is low 
intake of fiber (adjusted OR, 2.46; 
95% CI, 1.15–5.27) 
 
CD – Crohn’s disease  
  
Supplemental Table 7. Animal studies of artificial sweeteners and maltodextrin 




CD-like ileitis-prone SAMP 
mice 
 
Ileitis-free control AKR  
 
 




inflammation scores, E. coli 
infiltration of ileum mucosa, 
malX gene expression 
Splenda did not alter ileal inflammatory scores, 
percent of SM-abnormal mucosa, 3D morphology  of 
cobblestone lesions 
Supplementation of Splenda increased 
Proteobacteria, no significant impact on 
Bacteroidetes or Firmicutes abundances, increased 
Enterobacteria  
MPO activity in Splenda-supplemented SAMP mice 
2.7 times higher compared to control SAMP 
Increased E. coli abundance and penetration into ileal 
mucosa 
Increased bacterial malX gene expression in treated 
SAMP mice compared to control SAMP (P=0.03), 
undetectable malX in all AKR 
Bian (2017) 
 
C57BL/6J male mice TNF-α, iNOS, fecal 
microbiome 6 month supplementation of saccharin in drinking 
water increased iNOS and TNF-α (p<0.05) in liver, 
decreased Dorea and Ruminococcus  (Clostridiales), 




CD-1 mice Fecal microbiome 
4 week supplementation of neotame in drinking 
water decreased α-diversity, altered β-diversity, 
decreased genes responsible for butyrate synthesis 
(SCFA), decreased Firmicutes and increased 
Bacteroidetes phyla  
Nickerson (2012) Ileal and colonic human tissue 
culture 
Epithelial biofilm formation 
and adhesion of LF82 AIEC 
strain, malX gene expression 
MDX promotes biofilm formation of LF82 and its 
adhesion to epithelial cells of CD tissue but not 
invasiveness, malX gene more expressed in ileal 
mucosa of CD patients compared to controls (71% 
positive vs. 18% positive) 
Nickerson (2014) a) Cell culture (Human 
intestinal epithelial cells, 
human and murine 
macrophages) 




a) MDX supplementation on healthy epithelial and 
macrophage cells infected with Salmonella increased 
viability of Salmonella  
b) MDX consumption in drinking water alone did not 
CD – Crohn’s disease 
  
b) Animal model: C57BL/6 
mice (Salmonella colitis model) 
colonization, bacterial 
localization score 
affect intestinal inflammation, though enhanced 
Salmonella colonization and increased bacterial 
localization score in colonic epithelial cells 
Suez (2014) a) Animal model:  C57Bl/6 
mice 
b) In vitro: Fecal  culture (of 
C57BI/6 naïve mice) 
c) (Part of) prospective cohort 
study 
a) Fecal microbiome 
b) Fecal microbiome 
c) Artificial sweetener 
consumption, fecal 
microbiome (172 from cohort 
of 381 non-diabetic 
individuals) 
a) Mice consuming saccharin in drinking water 
compared to glucose had increased relative 
abundance of Bacteroides and Enterobacteriaceae, 
decreased Lactobacilli and some Clostridiales  
b) Fecal matter of mice grown on medium with 
saccharin, increased Bacteroidetes and reduction in 
Firmicutes phyla  
c) Increased relative abundance of 
Enterobacteriaceae, Deltaproteobacteria and 
Actinobacteria with higher AS consumption 





Key outcome measures  Key findings 
Watt J 
(1971) 
Adult male albino 
guinea pig 
Weight change, stools 
and FOBT, and 
histopathology   
Exposure to carrageenan (5% w/v in drinking water consumed ad libitum for 20 to 45 days) 
led to weight loss (15 – 25% in exposed group vs none in control group),loose stools (100% 
in exposed group vs none in control group), positive fecal occult blood test  (100% in 
exposed group vs none in controlled group) and ulcerations (86% in exposed group vs none 
in control group) 
Al-Suhail 
A (1984) 
Young adult New 
Zealand white 
rabbits  
Weight change, stools 
and, histopathology  
Exposure to carrageenan (1%w/v in drinking water consumed ad libitum for up to 63 days) 
led to (a) weight loss (-1.47g vs + 1.310g gain in control group), (b) loose stools, positive 
fecal occult blood test, (c) mucosal ulceration and increased inflammatory cell infiltrate   
Swidsinski 
A (2008) 
Il10-/- mice  Intestinal permeability  Exposure to Polysorbate-80 (100µl 2%  solution via gavage orally for 3 weeks) led to an 










Exposure to Polysorbate-80 (deposited directly into lumen of cannulated rat intestinal 
mucosa) led to increased intestinal permeability andincreased levels of N-acetyl-beta-
glucosamine and decreased levels of phospholipase A2. There were no changes in alkaline 





mice and  




microbiota and its 
inflammatory potential  
Exposure to CMC and P80 (1%w/v in drinking water and 0.1%, 0.5% in chow) led to modest 
weight gain, reduced mucus thickness and changes in microbiota composition (including 
increases in health associated and decreases in IBD-associated species). Transplanting the 
cecal contents of emulsifier-treated mice into germ free mice caused microbiota 
encroachments and low grade inflammation that correlated with altered microbiota 
species composition and elevated levels of fecal lipopolysaccharide (LPS) and flaggelin. 











activity index and 
inflammation and  
Mice with and without induced inflammation were treated with varying doses (None or 
1.7mg/kg or 8.3mg/kg or  41.7mg/kg) of carrageenan, for one week via gavage. 
Carrageenan exposure led to weight loss in all mice with induced inflammation. Weight 
loss was dose dependent (5.1%+/-1.01 for none versus 15.7%+/-1.43 for 41.7mg/kg). In 
mice with induced inflammation, high-dose  carrageenan exposure led to a 2.08-fold 
increase in histological activity index (HAI) . Amongst mice with induced inflammation, 
carrageenan exposure led to i a decreased T-regs ratio, increased serum levels of pro-
inflammatory cytokines (e.g. TNF, IL-6, IL-4, INF-γ) and up-regulation of TLR, NFƙB; 
compared to the group that was not exposed to carrageenan, the high-dose carrageenan 
group had a 1.29-fold, 1.32-fold up-regulation in TLR and NF-kB, respectively. Likewise, T-
regs ratio was lowest, and cytokine levels were highest in the group exposed to the highest 




C57BL/6 mice Weight, colon length,  
inflammation and 
microbiome  
Emulsifiers had no effect on weight or colon length. Exposure to three isomers of 
carrageenan (20mg/L in drinking water) led to an increase in histological score of 
inflammation and increased levels of serum TNF-α.  
ι-carrageenan increased bacterial richness and diversity but ƙ-carrageenan had the 
opposite effects. All isomers of carrageenan decreased the abundance of Bacteroidetes 
and Verrucomicrobia but increased Firmicutes. Proteobacteria increased in response to ι 
and λ-carrageenan but decreased in relation to κ-carrageenan. (c) 
Chassaing 
B (2017)  
M-SHIME (in 
vitro model of 
human 
microbiome) 
placed into   
C57BL/6 and RAG 
-/- mice 
 
Microbiome and its 
inflammatory potential; 
gene expression  
 
 
CMC and PS80 did not impact the microbiota of ASF mice. Exposure to PS80 (but not CMC) 
led to clear, direct changes in bacterial diversity (increased Proteobacteria, 
Enterobacteriacae and decreased Bacterioadaccea) in  M-SHIME model inoculated with 
human faces.   
Exposure to CMC and PS80 in the M-SHIME model induced changes in genes related to 
flagella expression. Levels of bioactive flaggelin increased rapidly in response to CMC and 
more slowly in response to PS80, with PS80 also inducing increases in LPS. A clear dose-
dependent relationship was not observed. Compared to water treated M-SHIME, CMC and 
PS80 treated M-SHIME samples inserted into RAG -/- mice significantly increased IL-6 
levels. Certain M-SHIME perturbations induced by CMC and PS80 persisted when 
transferred into germ free mice. 
 
CD – Crohn’s disease  
  
Supplemental Table 9. Clinical trials of low nanoparticle diets. 
Author 
(year) 
Study design Sample 
size 










treated ileal or ileo-
colonic CD 
Crohn's disease activity index 
(CDAI) and corticosteroid 
requirement 
In the diet group there was a progressive 
decrease in CDAI from entry (392 +/- 25) to 
month 4 (145 +/- 47) (P = 0.002 vs control 
group) and seven patients were in remission 
(CDAI <150). In the control group there was no 
significant change to baseline levels (302 +/- 28 
on entry and 295 +/- 25 at month 4), 
Corticosteroid intake was reduced more in the 









to sham diet or 
microparticle 
free diet and to 
low calcium or 
normal calcium 
intake diet.  
83 active CD Crohn's disease activity index, 
Van Hees index, quality of life 
and a series of objective 
measures of inflammation 
including erythrocyte 
sedimentation rate, C-reactive 
protein, intestinal permeability 
and faecal calprotectin 
Dietary manipulation provided no added effect 
to corticosteroid treatment on any of the 
outcome measures during the dietary trial (16 
weeks) or follow-up (to 1 year);  
CD – Crohn’s disease 
 

